Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $6.25

Humacyte, Inc. (NASDAQ:HUMA) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.25.

A number of equities research analysts have recently commented on the company. HC Wainwright increased their target price on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. TD Cowen lowered their price target on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research report on Wednesday, June 17th. Benchmark upped their price target on shares of Humacyte to $2.00 and gave the stock a “speculative buy” rating in a research note on Monday, June 1st. Wall Street Zen downgraded shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander sold 45,887 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the chief financial officer owned 267,213 shares in the company, valued at $240,491.70. This represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius purchased 56,818 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $0.88 per share, for a total transaction of $49,999.84. Following the acquisition, the director owned 148,025 shares of the company’s stock, valued at approximately $130,262. The trade was a 62.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in shares of Humacyte in the 4th quarter worth $25,000. Atom Investors LP bought a new position in shares of Humacyte during the fourth quarter valued at $25,000. Prudential Financial Inc. bought a new position in shares of Humacyte during the second quarter valued at $28,000. Financial Advisors Network Inc. purchased a new stake in shares of Humacyte during the second quarter valued at $28,000. Finally, Equitable Holdings Inc. purchased a new stake in shares of Humacyte during the third quarter valued at $29,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Stock Performance

Shares of HUMA opened at $0.66 on Friday. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. The stock has a market cap of $147.58 million, a P/E ratio of -1.17 and a beta of 2.52. The business’s 50 day moving average price is $0.96 and its 200-day moving average price is $0.96. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.84.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. Equities research analysts anticipate that Humacyte will post -0.34 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.